NCT05058482

Brief Summary

This clinical trial is to verify the safety and effectiveness of the Non-adhesive Liquid Embolic System(NALES) produced by Suzhou Hengrui Hongyuan Medical Technology Co., Ltd. in the process of clinical use to support the application of the National Medical Products Administration ( NMPA) product registration approval.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
116

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Dec 2021

Typical duration for not_applicable

Geographic Reach
1 country

13 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 24, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 27, 2021

Completed
2 months until next milestone

Study Start

First participant enrolled

December 2, 2021

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 17, 2023

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

October 17, 2024

Completed
Last Updated

May 6, 2022

Status Verified

September 1, 2021

Enrollment Period

1.9 years

First QC Date

September 24, 2021

Last Update Submit

May 4, 2022

Conditions

Keywords

Non-adhesive Liquid Embolic System

Outcome Measures

Primary Outcomes (1)

  • Effective embolization rate of malformed masses

    Number of effective embolization subjects / Total number of subjects x 100%.Definition of effective embolization : Postoperative DSA angiographic malformation volume decreased ≥50%. Volume of malformed groups = length × width × height /2.

    Immediately after surgery

Secondary Outcomes (3)

  • MRS score

    1,6,12months after surgery

  • Technical success rate

    Immediately after surgery

  • Catheter performance evaluation

    Immediately after surgery

Other Outcomes (1)

  • Incidence of major adverse events related to device or surgical procedures within 1 month after surgery

    1 month after surgery

Study Arms (2)

Non-adhesive Liquid Embolic System(NALES)

EXPERIMENTAL
Device: embolism

Onyx Liquid Embolic System& Marathon Flow Directed Micro Catheter

ACTIVE COMPARATOR
Device: embolism

Interventions

embolismDEVICE

Cerebral arteriovenous malformation embolism

Non-adhesive Liquid Embolic System(NALES)Onyx Liquid Embolic System& Marathon Flow Directed Micro Catheter

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18-70 years old, no gender limit.
  • The patient was diagnosed as cerebral arteriovenous malformation .
  • The patient had no history of bAVM treatment, including intervention, surgery or radiotherapy .
  • Spetzler Martin, grade I-IV .
  • The patient voluntarily signed the informed consent.

You may not qualify if:

  • History of heparin allergy.
  • The patient is allergic to contrast media.
  • Severe hepatic and renal insufficiency (serum creatinine ≥1.5 times the upper limit of normal value, alanine aminotransferase ≥3 times the upper limit of normal value, aspartate aminotransferase ≥3 times the upper limit of normal value).
  • Patient has irreversible coagulopathy (INR \> 1.5).
  • Intracranial hemorrhage 1 week before treatment.
  • MRS ≥4 due to neurological dysfunction.
  • Patients with planned malformation resection after embolization.
  • Blood flow related aneurysms of supplying artery that need to be treated by other methods.
  • Complicated with severe cerebral artery stenosis.
  • Brain tumors that require recent surgery.
  • Complicated with proliferative cerebrovascular disease.
  • Pregnant or lactating women.
  • Participants who have participated in other clinical trials within the last 3 months and failed to reach the end point.
  • The number of embolism is expected to be greater than or equal to 4 times during the study period (within 1 year).
  • Subjects deemed unsuitable for this study by the investigator.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (13)

Zhujiang Hospital of Southern Medical University

Guangzhou, Guangdong, 510280, China

NOT YET RECRUITING

Nan Fang Hospital

Guangzhou, Guangdong, 510515, China

NOT YET RECRUITING

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China

NOT YET RECRUITING

The First Affiliated Hospital of Harbin Medical University

Harbin, Heilongjiang, China

NOT YET RECRUITING

Henan Provincial People's Hospital

Zhengzhou, Henan, China

RECRUITING

Zhongnan Hospital of Wuhan University

Wuhan, Hubei, 430071, China

NOT YET RECRUITING

The First People's Hospital of Changzhou

Changzhou, Jiangsu, China

NOT YET RECRUITING

Nanjng Drum Tower Hospital

Nanjing, Jiangsu, 210008, China

NOT YET RECRUITING

General Hospital of Eastern Theater Command

Nanjing, Jiangsu, China

NOT YET RECRUITING

The Second Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China

NOT YET RECRUITING

Huashan Hospital ,Fudan University

Shanghai, Shanghai Municipality, China

NOT YET RECRUITING

Shanghai Changhai Hospital

Shanghai, Shanghai Municipality, China

RECRUITING

The Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, 322000, China

NOT YET RECRUITING

MeSH Terms

Conditions

Intracranial Arteriovenous Malformations

Interventions

Embolic Protection Devices

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesCentral Nervous System Vascular MalformationsNervous System MalformationsArteriovenous MalformationsVascular MalformationsCardiovascular AbnormalitiesCardiovascular DiseasesVascular DiseasesIntracranial Arterial DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Intervention Hierarchy (Ancestors)

Prostheses and ImplantsEquipment and Supplies

Central Study Contacts

Jianmin Liu, Doctor

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 24, 2021

First Posted

September 27, 2021

Study Start

December 2, 2021

Primary Completion

October 17, 2023

Study Completion

October 17, 2024

Last Updated

May 6, 2022

Record last verified: 2021-09

Locations